Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corporation, filed a Form 4 on August 19, 2026, disclosing the exercise of 9,500 stock options and the sale of 9,501 shares of common stock on August 18, 2026, pursuant to a pre-arranged Rule 10b5-1 trading plan.
Key Highlights
- Option exercise: Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share, held indirectly through a family trust.
- Shares sold: A total of 9,501 shares were disposed of across ten separate transactions on August 18, 2026, at weighted average prices ranging from $509.4837 to $518.6476.
- 10b5-1 plan: The transactions were made pursuant to a pre-arranged trading plan adopted by Rothblatt on November 7, 2025, covering up to 1,734,410 stock options expiring March 15, 2027.
- Plan duration: The plan continues until the earlier of the exercise of all 1,734,410 options or December 31, 2026.
- Remaining beneficial ownership: Following the transactions, Rothblatt beneficially owned, directly and indirectly, shares across multiple holdings including 40,513 directly and 332,864 indirectly through a family trust, among other positions.
- Remaining options: 113,410 stock options remain beneficially owned indirectly through a family trust following the reported exercise.
Rothblatt's August 2026 Option Exercise and Share Sale at United Therapeutics
According to the filing, Martine A. Rothblatt, serving as Chairperson and CEO of United Therapeutics Corporation (NASDAQ:UTHR), exercised 9,500 stock options on August 18, 2026, at an exercise price of $135.42 per share. The options, which carry an expiration date of March 15, 2027, are held indirectly through a family trust in which Rothblatt shares investment power and Rothblatt and immediate family members are beneficiaries. Following the exercise, the trust held 333,943 shares of common stock.
The filing disclosed that 9,501 shares were then sold across ten separate tranches on the same date. The transactions were executed in multiple trades within each tranche, with weighted average prices reported ranging from $509.4837 for the first tranche of 239 shares to $518.6476 for the final tranche of 441 shares. The filing notes that full information on the individual trade prices within each tranche is available upon request to the SEC staff, the issuer, or a security holder. After all sales, the trust's holding stood at 324,443 shares.
All transactions were conducted under a Rule 10b5-1 trading plan that Rothblatt adopted on November 7, 2025. The plan is designed to cover the exercise of up to 1,734,410 stock options, all expiring March 15, 2027, and will terminate on the earlier of full exercise of those options or December 31, 2026. Following the reported activity, 113,410 stock options remain beneficially owned indirectly through a family trust. The filing was signed by John S. Hess, Jr. under Power of Attorney on August 19, 2026.
What Was Disclosed
The filing reported the exercise of 9,500 stock options and the sale of 9,501 shares of United Therapeutics common stock by CEO Martine A. Rothblatt on August 18, 2026, all conducted under a pre-arranged 10b5-1 trading plan adopted November 7, 2025.



Please wait processing your request...